- Home
- TSI vs ZYXI Comparison
TSI vs ZYXI Comparison
Compare TSI & ZYXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSI
- ZYXI
- Stock Information
- Founded
- TSI 1987
- ZYXI 1996
- Country
- TSI United States
- ZYXI United States
- Employees
- TSI N/A
- ZYXI N/A
- Industry
- TSI Investment Managers
- ZYXI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- TSI Finance
- ZYXI Health Care
- Exchange
- TSI Nasdaq
- ZYXI Nasdaq
- Market Cap
- TSI 234.6M
- ZYXI 72.3M
- IPO Year
- TSI N/A
- ZYXI N/A
- Fundamental
- Price
- TSI $4.91
- ZYXI $2.40
- Analyst Decision
- TSI
- ZYXI Buy
- Analyst Count
- TSI 0
- ZYXI 3
- Target Price
- TSI N/A
- ZYXI $6.00
- AVG Volume (30 Days)
- TSI 106.8K
- ZYXI 252.9K
- Earning Date
- TSI 01-01-0001
- ZYXI 07-24-2025
- Dividend Yield
- TSI 7.46%
- ZYXI N/A
- EPS Growth
- TSI N/A
- ZYXI N/A
- EPS
- TSI N/A
- ZYXI N/A
- Revenue
- TSI N/A
- ZYXI $172,401,000.00
- Revenue This Year
- TSI N/A
- ZYXI N/A
- Revenue Next Year
- TSI N/A
- ZYXI $19.55
- P/E Ratio
- TSI N/A
- ZYXI N/A
- Revenue Growth
- TSI N/A
- ZYXI N/A
- 52 Week Low
- TSI $4.48
- ZYXI $1.66
- 52 Week High
- TSI $4.87
- ZYXI $10.62
- Technical
- Relative Strength Index (RSI)
- TSI 44.20
- ZYXI 56.38
- Support Level
- TSI $4.87
- ZYXI $2.51
- Resistance Level
- TSI $4.99
- ZYXI $2.72
- Average True Range (ATR)
- TSI 0.05
- ZYXI 0.18
- MACD
- TSI -0.01
- ZYXI 0.03
- Stochastic Oscillator
- TSI 42.11
- ZYXI 69.51
About TSI TCW Strategic Income Fund Inc.
Tcw Strategic Income Fund Inc operates as a closed-end management investment company. Its investment objective is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as airlines, banks, beverages, biotechnology, chemicals, computers, diversified financial services, entertainment and others.
About ZYXI Zynex Inc.
Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company operates business as one operating segment which includes two revenue types: Devices and Supplies. Its markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others.